In addition, the York-based firm says Dr Stuart Best has joined the company as senior director of operations.
Dr Roblin joins the firm from Pfizer global r&d where he was most recently senior vice president r&d, research head and site director. His experience crosses therapeutic areas within the spectrum of small and large molecule r&d.
Dr Best was previously head of bioanalysis at Merck, Scotland. His career has been distinguished by his leadership in applying progressively sophisticated analytical technologies to this expanding and complex area of chemistry. Prior to Merck, Dr Best developed his reputation as an authority in the use of mass spectrometry in bioanalysis at Charles River (Inveresk).
Xceleron makes key appointments
Hires board member and senior director of operations